Participation in Multicenter Research Studies

1990-1992  Cyclosporine-High Risk Corneal Transplantation Study
1990-1996  VISX Photorefractive Keratectomy Study
1990-1995  Fibronectin Eyedrops in the Treatment of Nonhealing Corneal Ulcers
1992-1993  Efficacy of Carbomer Gel Versus Hypotears in Dry Eye Patients
1992-1994  Efficacy and Safety of Rimexolone Ophthalmic Suspension Versus Pred Forte 1% for the Treatment of Uveitis
1992-1993  Efficacy and Safety Evaluation of Lodoxamide 0.1% Ophthalmic Solution Versus Placebo in Vernal Keratoconjunctivitis
1992-1993  Adjunctive Therapy with Galardin™ Matrix Metalloproteinase Inhibitor in Patients with Corneal Ulcers Caused by Infection
1992-1993  Adjunctive Therapy with Galardin™ Matrix Metalloproteinase Inhibitor in Patients with Corneal Ulcers Caused by Rheumatoid Arthritis
1992-1993  A Prospective, Randomized, Double-Masked, Parallel Group, Two Week, Multicenter Comparison Trial of the Ocular Efficacy and Safety Of Voltaren Ophthalmic 0.1% Solution with That of Acular 0.5% Ophthalmic Solution in Patients with Acute Seasonal Allergic Conjunctivitis
1993-1994  Safety and Efficacy of Lotoprednol Etabonate in Acute Anterior Uveitis
1994-1995  A Clinical Study Comparing the Ocular Safety and Efficacy Of Acular With Livostin And Vehicle in Subjects with Seasonal Allergic Conjunctivitis
1994-1996  A Double-Masked, Double-Dummy, Randomized, Acyclovir Controlled, Parallel Group Study to Compare the Efficacy and Safety of Famciclovir With Acyclovir in The Treatment Of Patients with Ophthalmic Zoster
1995-1996  A Dose-Ranging Study Evaluating the Safety, Tolerability, and Efficacy of Cyclosporine and Vehicle Ophthalmic Emulsions in The Treatment of Moderate to Severe Keratoconjunctivitis Sicca
1996-1996  Comparison of Lotoprednol Etabonate in Acute Anterior Uveitis and Placebo in the Treatment of Inflammation Following Cataract Surgery with Intraocular Lens Implantation
1996-1997  Multicenter Comparison of the Comfort and Efficacy of Genteal Ophthalmic Lubricant Solution Versus Refresh Plus Ophthalmic Lubricant Solution in the Treatment of Patients with Dry Eye Syndrome
1997-1998  A Safety and Efficacy Assessment of Hyaluronidase Solution Injected Into The Vitreous Body of The Eye to Hasten the Clearing of Blood from the Vitreous
Joseph Tauber, M.D.  
Participation in Multicenter Research Studies (continued)

1997-1998  
A Multicenter, Double-Masked, Randomized, Vehicle-Controlled, 
Parallel-Group Study of the Safety and Efficacy of Cyclosporine 0.05% 
And 0.1% Ophthalmic Emulsions Used Twice Daily for Up to One Year 
In Patients with Moderate to Severe Keratoconjunctivitis Sicca

1998-1999  
A Six Month, Multicenter, Triple-masked, Placebo-Controlled 
Adjunctive Therapy Study of the Safety and Efficacy of AL-6221 
0.0015% and AL-6221 0.004% Ophthalmic Solution in Patients With 
Open Angle Glaucoma or Ocular Hypertension Maintained on Timoptic 0.5%

1998-2000  
A Phase III Study of MDX-RA Compared with Placebo Administered in 
Patients Undergoing Extracapsular Extraction with Phacoemulsification 
For Cataract

1998-1999  
A Multicenter, Open-Label, Phase 2 Study Extension Evaluating the 
Safety of Cyclosporine 0.1% Ophthalmic Emulsion Used Twice Daily for 
Up to One Additional Year in Patients with Moderate to Severe 
Keratoconjunctivitis Sicca

1998-2000  
A Multicenter, Open-Label, Phase 3 Study Extension Evaluating the 
Safety of Cyclosporine 0.1% Ophthalmic Emulsion Used Twice Daily for 
One Additional Year in Patients with Moderate to Severe 
Keratoconjunctivitis Sicca Previously Dosed for 6 to 12 Months with 
Cyclosporine 0.05% or 0.1%

1998-2001  
Safety and Efficacy Study of Vitrase (Hyaluronidase) for Ophthalmic 
Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage 
Study

1998-1999  
RUF366 A Pilot Study of Zenarestat 0.3% (RUF366) For the 
Treatment of Corneal Epitheliopathy Associated with Diabetes Mellitus

1998-1999  
Genteal-Gel Ophthalmic Lubricant in the Treatment of Patients with 
Moderate to Severe Dry Eye Syndrome

1999-2005  
A 48 Month, Multicenter, Randomized, Double-Masked, Placebo-
Controlled, Clinical Study to Evaluate the Effectiveness and Safety Of 
Oral Memantine In Daily Doses Of 20mg and 10mg In Patients With 
Chronic Open Angle Glaucoma at Risk for Glaucomatous Progression

2000-2001  
Cyclosporine 0.05% Ophthalmic Emulsion vs Tears Naturale Free Used 
Twice Daily in Increasing Daily Lens Comfort and Wear Time 
Joseph Tauber, M.D., Primary Investigator

2000-2001  
Memantine Oral Doses of 20mg and 10mg In Patients with Chronic 
Open-Angle Glaucoma at Risk for Glaucomatous Progression

2001-2002  
Inspire 365 Ophthalmic Solution vs Placebo in Patients with Moderate 
to Severe Dry Eye Disease

2001-2002  
A Multicenter Evaluation of Strategies to Optimize the Tolerability of 
Restasis 0.05% Ophthalmic Emulsion

2001-2004  
Randomized, 5 Year Postmarketing Safety Study of Xalatan Compared 
to “Usual Care” in Patients with Open-Angle Glaucoma or Ocular 
Hypertension

2001-2004  
A Three Month Clinical Study Comparing the Efficacy and Tolerability 
of Alphagan and Xalatan in subjects with Chronic Open-Angle Glaucoma 
or Chronic Ocular Hypertension Presently on Topical Beta Blockers

Updated 1/20/2020
Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Intermediate, or Pan-Uveitis.

A Multi-Center, Parallel, Randomized, Double-Masked, Vehicle-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Testosterone 0.01%, 0.1%, and 0.3% Ophthalmic Solutions Administered Twice Daily for 16 weeks in Patients with Keratoconjunctivitis Sicca.

A Multi-Center, Double- Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of IN8365 Ophthalmic Solution vs. Placebo in Subjects with Dry Eye Disease.

A Prospective, Randomized, Parallel-group, Multi-center, Double-masked Trial Comparing the Efficacy and Safety of 1.5% Levofloxacin Ophthalmic Solution with 0.3% Ofloxacin Ophthalmic Solution for Treating Bacterial Keratitis.

A 21 Day, Pilot, Multicenter, Investigator-masked Randomized Parallel Comparison of the Safety and Efficacy of Gatifloxacin 0.3% Ophthalmic Solution Compared with Ciprofloxacin 0.3% Ofloxacin Ophthalmic Solution in Patients with Acute Bacterial Corneal Ulcers.

A Multi-Center, Parallel Group, Double- Masked, Randomized, Placebo-Controlled Study of Multiple Ocular Instillations of Diquafasol Tetrasodium Ophthalmic Solution, 2% in Subjects with Dry Eye Disease.

Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multi-Center, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel Group, 26 Week Study.

A 24 week randomized, double-blind, multicenter, parallel-group, placebo-controlled evaluation of the safety and efficacy of 0.3% and 1% pimecrolimus ophthalmic suspensions used twice daily in patients with moderate to severe keratoconjunctivitis sicca.

Optimization of Clinical Testing in Patients with Dry Eye.

A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 compared to Vigamox™ in the Treatment of Bacterial Conjunctivitis.

Rebamipide Ophthalmic Suspension, 0.3% compared to Ciprofloxacin 0.3% Ophthalmic Suspensions in the Treatment of Dry Eye.

A Multi-Center, Placebo-Controlled, Parallel Group, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior- or Pan-Uveitis.

A Double-Masked, Placebo-Controlled, Parallel Group, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Quiescent Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior- or Pan-Uveitis.

A Double-Masked, Placebo-Controlled, Parallel Group, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Anterior Uveitis.

A Multi-center, Placebo-Controlled, Randomized, Parallel-Group Dose-Ranging Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure Following Penetrating Keratoplasty with LX201 Implantation In Subjects Who Are At Increased Immunological Risk.
### Participation in Multicenter Research Studies (continued)

<table>
<thead>
<tr>
<th>Year</th>
<th>Study Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007-2009</td>
<td>A Multi-center, Placebo-Controlled, Randomized, Parallel-Group Dose-Ranging Study to Assess the Efficacy and Safety of LX201 Implantation for the Prevention of Corneal Allograft Rejection Episodes or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty</td>
</tr>
<tr>
<td>2007-2008</td>
<td>A Phase III Study of the Efficacy and Safety of Cyclosporine Ophthalmic Solution, 0/1% (STA-603) Compared to Vehicle in Subjects with Moderate to Severe Dry Eye Syndrome</td>
</tr>
<tr>
<td>2007-2008</td>
<td>A Phase 2b Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis</td>
</tr>
<tr>
<td>2008-2009</td>
<td>A Multi-Center, Open-Label, Randomized, Pilot Study of the Safety and Efficacy of Azasite Ophthalmic Solution 1% in Combination with Mechanical Therapy vs. Mechanical Therapy Alone in Subjects with Blepharitis</td>
</tr>
<tr>
<td>2008-2009</td>
<td>Efficacy and Safety of COL-101 for the Treatment of Blepharitis in Patients with Facial Rosacea</td>
</tr>
<tr>
<td>2008-2009</td>
<td>A Phase II Randomized, Masked, Parallel-Group Study of Safety and Preliminary Efficacy of the Latanoprost Punctum Plug Delivery System in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension</td>
</tr>
<tr>
<td>2008-2009</td>
<td>An Open-Label Proof-Of-Concept Study to Assess The Effects of Two AIN457 Doses (on Day 1 and Day 22) In Patients With Noninfectious Uveitis</td>
</tr>
<tr>
<td>2009-2009</td>
<td>A Multicenter, Parallel Group, Double-masked, Randomized, Placebo-controlled Study of The Effects of Diquafosol tetrasodium Ophthalmic Solution, 2% In Subjects with Dry Eye Disease and a Central Corneal Staining Score of 3 (NEI Scale)</td>
</tr>
<tr>
<td>2009-2009</td>
<td>An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in the USA</td>
</tr>
<tr>
<td>2009-2012</td>
<td>A Device Evaluation Study to Assess the Physical and Clinical Performance of Prototype Punctal Plug Design Iterations</td>
</tr>
<tr>
<td>2009-2009</td>
<td>An Open-Label, Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS in Subjects with Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG))</td>
</tr>
<tr>
<td>2009-2009</td>
<td>A Phase I/II Prospective, Randomized, Double Masked, Vehicle and Comparator Controlled, Dose Ranging Study of CP-690,550 In Subjects with Dry Eye Disease</td>
</tr>
<tr>
<td>2009-2009</td>
<td>A Multi-Center, Open Label Randomized Pilot Study of the Safety and Efficacy of Azasite Ophthalmic Solution, 1% in Combination with Mechanical Therapy versus Mechanical Therapy Alone in Subjects with Blepharitis</td>
</tr>
<tr>
<td>2009-2010</td>
<td>A Clinical Safety and Efficacy Evaluation of Zylet® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension) compared to Lotemax® (loteprednol etabonate ophthalmic suspension 0.5%), Tobramycin Ophthalmic Solution USP, 0.3%, and the Vehicle of Zylet® for the Treatment of Blepharoconjunctivitis in Pediatric Subjects</td>
</tr>
<tr>
<td>2009-2010</td>
<td>A Multi-Center, Double Masked, Placebo-Controlled, Parallel-Group, Randomized Study of the Safety and Efficacy of Azithromycin Ophthalmic Solution, 1% versus Placebo for Four Weeks in Subjects with Dry Eye Disease</td>
</tr>
<tr>
<td>2010-2011</td>
<td>A Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Multicenter, Exploratory Study Assessing Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome</td>
</tr>
</tbody>
</table>

*Updated 1/20/2020*
2011-2011 A Randomized, Multi-Center, Double-Masked, Vehicle- Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% versus Vehicle for Four Weeks in Subjects with Blepharitis

2011-2013 A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate (1%) in Patients with Non-Infectious Anterior Segment Uveitis

2012-2013 A Randomized, Double-Masked, Parallel –Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-502 (1.0% Azithromycin and 0.1% Dexamethasone) Compared to Azasite alone, Dexamethasone 0.1% alone and Vehicle in the Treatment of Patients with Non-Bacterial Blepharitis

2012-2013 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of 2% Rabamipide versus placebo in the treatment of Dry Eyes.

2012-2013 A Randomized, Double-masked, Placebo-controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution versus Placebo in subjects with Dry Eye Syndrome.

2013-2013 A Phase 3, Multicenter, Randomized, Double Masked and Placebo Controlled Study Evaluating the Efficacy of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Currently Using Artificial Tears (OPUS-2)

2013-2013 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of GevokizumAb in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis

2013-2013 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of GevokizumAb in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan- uveitis Currently Controlled with Systemic Treatment

2013-2014 Ophthalmic AGN195263 for the Treatment of Meibomian Gland Dysfunction

2014- 2015 A Multi-Center, Double-Masked, Randomized, Placebo Controlled Study of EBI-005 Ophthalmic Solution versus Placebo in subjects with Dry Eye Syndrome

2014-2015 A Double-Masked, Randomized, Multicenter, Placebo Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders

2014-2015 A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation

2014-2015 A Phase 2, Double-Masked, Randomized, Vehicle Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease

2014-2016 Dry Eye Assessment and Management (DREAM) Study (NIH Sponsored Trial)

2014-2015 A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Disease

2014-2015 A Multicenter, Double-Masked, Parallel-Group, Vehicle Controlled Study to Assess the Efficacy and Safety of Rx-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain In Subjects Undergoing Cataract Surgery


2014-2015 Evaluation of a Lubricant Eye Drop on Tear Lipid Layer Thickness in Contact Lens Wearers

Updated 1/20/2020
Participation in Multicenter Research Studies (continued)

2015-2016  A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients with Anterior Uveitis

2015-2016  A Phase 3, Multicenter, Randomized, Double-masked, and Placebo Controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Disease and History of Recent Artificial Tear Use

2016-2017  Randomized, Double-Masked, Parallel Group Study of P - 321 Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Disease Assessing Safety and Efficacy Over 28 Days

2016-2017  A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared with Placebo to Assess Safety and Efficacy of Two Dose Concentrations of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients with Moderate to Severe Corneal Epithelial Disorders


2016 – 2018  A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects with Dry Eye Disease

2016-2018  Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Non-Infectious Anterior Segment Uveitis

2016-2017  A Phase 3, Multi-Center, Double-Masked, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate (BID and TID) versus Vehicle Gel for the Treatment of Ocular inflammation


2017 – 2019  A Phase 3 Randomized, Double-Masked, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects with Non-Infectious Anterior Uveitis

2017-2017  Randomized Comparison between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction

2017 – 2018  Development of a Photographic Ocular Surface Grading Scale for Corneal and Conjunctival Staining in Subjects with Dry Eye Complaints

2017 – 2018  Clinical Evaluation Following Use of Systane Balance in Subjects with Lipid-Deficient Dry Eye

2017 – 2018  A Single-Center, Evaluation of a Single Vectored Thermal Pulsation Treatment vs. Lifitegrast 5% Used Twice Daily in Patients with Inflammatory Meibomian Gland Disease

2018 – Present  A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients with Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
Joseph Tauber, M.D.  
Participation in Multicenter Research Studies (continued)

2018 – Present  
A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation

2018 – Present  
A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep™ in Subjects with Dry Eye Associated with Sjögren’s Syndrome

2018 – 2019  
A double-masked, randomized, multicentre, placebo-controlled, parallel-group study to access the safety and efficacy of SJP-0035 0.001% for the treatment of patients with Dry Eye Disease with moderate to severe corneal epithelial disorders

2018 – 2019  
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease

2018 – 2019  
Evaluation of the Clinical Efficacy and Tolerability of SYSTANE Complete in Adult Patients with Dry Eye Disease following Topical Ocular use for 4 Weeks: A Multicenter Trial

2018 – 2020  
A Phase III, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multi-center Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% Compared with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with Glaucoma or Ocular Hypertension - Spectrum 3 Study

2019 – 2020  
A Multi Center, Double-Masked, Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of HY02 in Subjects with Inflamed Meibomian Gland Dysfunction

2019 – 2019  

2019 – 2020  
A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants with Presbyopia

2019 – 2019  
Comparison between iLux and LipiFlow in the treatment of Meibomian Gland Dysfunction (MGD): A 12 month, Multicenter study

2019 – Present  
A 4 weeks, Phase II, multicenter, randomized, double-masked, vehicle-controlled, parallel group study with 12 weeks of follow-up to evaluate safety and efficacy of recombinant human Nerve Growth Factor (rhNGF) eye drops solution versus vehicle in patients with moderate to severe dry eye (DE)

2019 – Present  
An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients with Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis

2019 – Present  
Novaliq, NVU-003 Study: A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland Dysfunction

2019 – Present  
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects with Dry Eye Disease (STRIDE 3)

Updated 1/20/2020
2019 – Present  Thermal compression for optimization of keratometry in patients with Meibomian Gland Dysfunction before biometry